Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.

Researchers from Aglaeapharma Inc. and Alpherabio LLC reported the discovery and preclinical characterization of CC-10137, a nonopioid α2A-adrenergic receptor (α2AAR) agonist designed for peripheral activity.

Despite multiple analgesics on the market, current therapeutics often fail at achieving complete pain relief and are usually tied to undesired adverse effects. Recent studies have pointed to adenosine A3 receptor (A3AR) as a promising target for pain management.

Mindbeam AI has leveraged generative AI to accelerate the discovery of novel pain therapeutics predicted to have improved liver safety compared to acetaminophen.

Researchers from Alzecure Pharma AB and collaborators reported preclinical efficacy data on ACD-137, a selective negative allosteric TrkA modulator in models of peripheral neuropathy and osteoarthritis.